Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1)
a study on Tumor Solid Tumor Metastasis Metastatic Cancer Cancer, General Cancer Metastatic Neoplasms Neoplasm Metastasis Malignant Solid Neoplasm Malignant Neoplasm Malignant Tumor Tuberous Sclerosis TSC1 TSC2 Metastatic Neoplasm
Tumor Tumor, Solid Metastasis Metastatic Cancer Cancer Cancer Metastatic Tumors Neoplasms Neoplasm Metastasis Solid Tumor Advanced Solid Tumor Advanced Cancer Malignant Solid Tumor Malignant Solid Neoplasm Malignant Neoplasm Malignant Tumor TSC TSC1 TSC2 Metastatic Solid Tumor Metastatic Neoplasm TSC1 gene TSC2 gene Tissue agnostic Basket nab-sirolimus mTOR inhibitor nanoparticle albumin bound mammalian target of rapamycin mechanistic target of rapamycin tumor profile tuberous sclerosis complex 1 tuberous sclerosis complex 2 mTOR sirolimus ABI-009 FYARRO Precision Precision 1 Pathogenic alterations Pathogenic mutations Inactivating mutations Pathogenic inactivating TSC1 alterations Pathogenic inactivating TSC2 alterations
Lead Scientists at University of California Health
- Noah Federman, MD (ucla)
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers.
- Brian Schulte, MD (ucsf)
Dr. Brian Schulte is a hematologist-oncologist who cares for patients with sarcomas, rare cancers that develop in connective tissues (such as bone, muscle or cartilage) and can affect people of all ages. Working as part of a multidisciplinary team, he strives to ensure patients receive the best possible comprehensive care.
- accepting new patients
- Start Date
- Completion Date
- Aadi Bioscience, Inc.
- Phase 2 research study
- Study Type
- Expecting 120 study participants
- Last Updated